For patients established on a TKI, therapy is monitored using quantitative (q)RT-PCR to measure the amount of BCR-ABL, the causative fusion oncogene of CML [5]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.